Trial Profile
COPD-related (Chronic Obstructive Pulmonary Disease) Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Cholinergic receptor antagonists
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GSK
- 25 Apr 2011 New trial record